JGC
VINC

J. Goldman & Co’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

J. Goldman & Co’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,620
Closed -$360K – 542
2021
Q1 		$360K Hold
4,620
– – 0.01% 376
2020
Q4 		$301K Hold
4,620
– – 0.02% 310
2020
Q3 		$144K Buy
+4,620
New +$939K 0.01% 290

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

J. Goldman & Co's VINC Position: Q2 2022 in Review

J. Goldman & Co sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2022, closing a stake of 2,155 shares — an estimated $172K sold.

J. Goldman & Co first reported a position in VINC in Q3 2020 and held it in 6 quarters. The position peaked at $1.51M in Q2 2021. 51 funds tracked by Wall St. Rank hold VINC as of Q2 2022.

  • J. Goldman & Co reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • J. Goldman & Co sold 2,155 Vincerx Pharma, Inc. Common Stock shares in Q2 2022, an estimated $172K.
  • J. Goldman & Co first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • J. Goldman & Co's Vincerx Pharma, Inc. Common Stock position peaked at $1.51M in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.